This study is for subjects with solid cancers (gastrointestinal, lung, breast, prostate, lymphoma or cancer of the lymph nodes). The overall goal of this study is to identify plant-derived phytochemicals that can safely reduce systemic inflammation (inflammation throughout the entire body) in subjects with advanced cancer. The term "phytochemicals" refers to a wide variety of compounds produced by plants. They are found in fruits, vegetables, beans, grains, and other plants. This study will look at oligomeric procyanidin complex (OPC) and vitamin D3. OPC is the major part of Grape Seed Extract. Subjects with solid cancers (gastrointestinal, lung, breast, prostate, lymphoma or cancer of the lymph nodes) will receive grape seed extract alone once or twice a day for 21 days. Then subjects will begin taking Vitamin D-3 at a fixed dose for 42 days. It is anticipated that this study may last approximately 65 days.

This study aims to determine whether administering high dose thoracic radiotherapy (70 Gy) will improve median and 2-year survival compared with the standard dose of radiotherapy (45 Gy) in patients with limited stage small cell lung cancer. The study will also characterize the toxicities of the regimens.

The purpose of this research study is to see if memantine reduces nicotine desire in cigarette smokers. We want to know if people with a history of cancer who smoke will participate in a smoking cessation study and how well they will adhere to treatment during the study. The research study will compare the effects (good and bad) of memantine or placebo to see which is better.

Memantine has been approved for Alzheimer’s disease by the US Food and Drug Administration (FDA), but it has not been approved for use in smoking cessation treatments.

The main purpose of this study is to find out if the drug BKM120 is safe and has positive effects in people who have metastatic non-small cell lung cancer (NSCLC). The goal of this study is to find out if BKM120 has any effect in patients with non-small cell lung cancer with an activated PI3K pathway.
BKM120 is a medicine that has not been approved by the Food and Drug Administration for the treatment of people with this medical condition. BKM120 is currently not “on the market” in any country.

This is a study to determine the clinical utility of the Lung Cancer Risk Test for identifying individuals at high risk for lung cancer. To do this, we will measure expression of each gene comprised by the LCRT in normal bronchial epithelial cells collected from subjects who share the inclusion and exclusion criteria for the Lung Cancer Risk Test study (LCRT Study, Pro9742), except that they also have lung cancer. Subjects who agree to participate receive additional bronchial brushings and a blood test.These samples are analyzed and compared to data collected from the LCRT Study, to optimize a test to identify individuals at greatest risk of lung cancer. Data collected from the spirometry cohort will be applied to determine if gene expression and/or DNA variants associate with COPD or lung cancer and/or predict the worsening of COPD over the course of the study.

The purpose of this study is to compare the effects, good and/or bad, of cetuximab on advanced non-small cell lung cancer. The part of this study considered “investigational” is the combination of drugs used in this study for advanced non-small cell lung cancer. Participants will be randomized to receive either chemotherapy without cetuximab or chemotherapy with cetuximab.

If randomized to Group 1, participants will have six three-week cycles of chemotherapy with paclitaxel, carboplatin and bevacizumab. After these six cycles of chemotherapy, they will continue bevacizumab without the other drugs on the same schedule as before.

If randomized to Group 2, participants will have six three-week cycles of chemotherapy with paclitaxel and carboplatin.

If randomized to Group 3, participants will have six three-week cycles of chemotherapy with cetuximab, paclitaxel, carboplatin and bevacizumab. After these six cycles of chemotherapy, participants will continue bevacizumab and cetuximab without the other drugs on the same schedule as before.

If randomized to Group 4, participants will have six three-week cycles of chemotherapy with cetuximab, paclitaxel and carboplatin. After these six cycles of chemotherapy, participants will continue cetuximab without the other drugs on the same schedule as before.

This study is for subjects that have been diagnosed with advanced or metastatic non-small cell lung cancer that has recurred or progressed after standard chemotherapy(s), or have been found to have a mutation in a protein found of the surface of cells (epidermal growth factor receptor; EGFR), or the cancer has responded to prior treatment with an EGFR tyrosine kinase inhibitor (TKI), such as erlotinib, but has since stopped responding. Merrimack Pharmaceuticals, the Sponsor of this study, wants to find out more about the study drug, MM-121. MM-121 is an antibody that binds to a specific protein found on the surface of cells. This protein, ErbB3, is involved with cell growth. In laboratory studies, MM-121 has been shown to bind to ErbB3 and hinder tumor cell growth. This study is going to look at the effects in humans. In the Phase 2 portion of the study, participants with certain observed tumor characteristics will be randomly assigned into one of two study drug groups:

• MM-121 plus erlotinib: 167 out of 229 participants (approximately 73% chance)
• Erlotinib alone: 62 out of 229 participants (approximately 27% chance)
The dose and dosing schedule that you receive will depend on when subjects enroll in the study. There will be a screening period prior to subjects receiving treatment on this study. For eligible subjects, they will receive infusion either once per week, once every other week, or once every three weeks at the scheduled visit. This is called Cycle 1. Once you have completed Cycle 1, you will begin Cycle 2 visits. Every eight weeks, the study doctor will evaluate the extent of disease. After subjects stop taking cycles of the study drug or decide to leave the study, they will have a follow up visit. The length of participation in the study will depend on the number of treatment cycles that you receive.

This study is designed to evaluate a new medication delivery technique to provide pain relief in the postoperative period following a VATS procedure. Participants in the study that receive the Paravertebral blocks in the study will either be assigned to a group of continuous or automated intermittent bolus infusion. The goal of the study is to discern whether one method of infusion is superior to the other in terms of controlling pain for patients undergoing the thoracotomy.

This is a randomized, Phase III, multicenter, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of MetMAb in combination with erlotinib as compared with treatment with erlotinib alone in patients with incurable NSCLC identified to be Met diagnostic positive.

The LCRT will be measured in NBEC samples in a subset of prospectively diagnosed lung cancer cases and matched lung cancer-free controls selected from a cohort of individuals without lung cancer at enrollment but who are at increased risk for lung cancer based on demographic criteria (≥ 50 years of age and ≥ to 20 pack years smoking history). The cohort will also include subjects who volunteer to receive a non-clinically indicated bronchoscopy. We will follow subjects until 15 cases are identified and confirmed, and 120 controls are selected. Following their bronchoscopy, each participant will receive an additional 5-10 brushings of the NBEC to test the validity of the LCRT. An addition 1-5 brushings will be done to establish a bank of NBEC and corresponding blood samples from study participants. We wil then compare gene expression in NBEC to gene analysis in blood samples to reach our goal of developing biomarkers assessable in blood samples and thus identify individuals at increased risk of lung cancer. Data collected from the spirometry cohort will be applied to determine if gene expression and/or DNA variants associate with COPD or lung cancer and/or predict the worsening of COPD over the course of the study.